Agreements reached under this partnership
Capital and Business Alliance- 1
Joint research and development concerning life sciences-related products
- 2
Development of new products and services through the mutual use of technologies, facilities and other assets owned by both companies
- 3
Mutual cooperation in sales activities, including market development and the creation of business opportunities in Japan and overseas
- 4
Strengthening both companies' business foundations through personnel exchanges and the implementation of other measures to promote collaboration
- 5
Other matters separately agreed in writing by both companies
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
The impact on our consolidated results for the fiscal year ending March 2027 is currently under review.
| Item | Details |
|---|---|
| Name of alliance partner | TAUNS Laboratories,Inc. |
| Alliance partner's business activities | Development, manufacture, sale and import/export of in vitro diagnostic products and research reagents; development, manufacture, sale and import/export of medical scientific measuring instruments, industrial measuring instruments and medical devices; contract research and other services |
| Alliance partner's location | Izunokuni, Shizuoka Prefecture |
| Alliance partner's capital | ¥400 million |
| Alliance partner's net sales | ¥14,369 million (fiscal year ending June 2026) |
| Alliance partner's operating income | ¥4,200 million (fiscal year ending June 2026) |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | Joint research and development concerning life sciences-related products, Development of new products and services through the mutual use of technologies, facilities and other assets owned by both companies, Mutual cooperation in sales activities, including market development and the creation of business opportunities in Japan and overseas, Strengthening both companies' business foundations through personnel exchanges and the implementation of other measures to promote collaboration, Other matters separately agreed in writing by both companies |
| Number of shares acquired | 21,600,000 shares (20.25% of the total number of shares issued as of 30 June 2026) |
| Acquisition price | ¥13,340 million |
| Shareholding ratio | 0.00％ → 20.27％ |
| Dispatch of directors and officers | As long as our voting rights ownership interest is at least 15%, we may nominate 1 director candidate after prior consultation with TAUNS Laboratories,Inc. |
| Shareholding Policy | If we intend to acquire additional shares in TAUNS Laboratories,Inc. or dispose of shares we hold, we will consult with TAUNS Laboratories,Inc. in advance. TAUNS Laboratories,Inc. will obtain our prior consent for certain issuances of shares or other securities that would reduce our voting rights ownership interest to below 15%. |
| Date of board resolution | 12 November 2026 |
| Contract Date | 12 November 2026 |
| Share Acquisition Date and Payment Date | 30 November 2026 (scheduled) |
| Impact on Business Performance | The impact on our consolidated results for the fiscal year ending March 2027 is currently under review. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The purpose is to strengthen クラボウ's life sciences and technology business by mutually utilizing TAUNS Laboratories,Inc.'s technologies, production capacity and sales network, together with クラボウ's gene extraction and analysis technologies, to create new products and services, strengthen production capabilities and expand sales opportunities.